Bleeding

4
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

CSL Behring
CSL BehringIL - Bradley
2 programs
1
1
Prothrombin complex concentratePhase 41 trial
autologous stored plateletsPhase 21 trial
Active Trials
NCT01248351Completed6Est. Mar 2011
NCT02557672Completed106Est. Jan 2022
M&
Merck & Co.RAHWAY, NJ
1 program
1
Desogestrel 75 micrograms POPPhase 41 trial
Active Trials
NCT01438736Unknown90
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
autologous stored plateletsPhase 2
Octapharma
OctapharmaAustria - Vienna
1 program
FibrygaN/A1 trial
Active Trials
NCT04106895Completed200Est. Feb 2020
Cellphire Therapeutics
1 program
Thrombosomes®N/A1 trial
Active Trials
NCT04619108No Longer Available
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
central venous catheter applicationN/A1 trial
Active Trials
NCT00448188Completed200Est. Mar 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL BehringProthrombin complex concentrate
Merck & Co.Desogestrel 75 micrograms POP
CSL Behringautologous stored platelets
OctapharmaFibryga
Heidelberg Pharmacentral venous catheter application

Clinical Trials (6)

Total enrollment: 602 patients across 6 trials

NCT02557672CSL BehringProthrombin complex concentrate

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Start: Aug 2016Est. completion: Jan 2022106 patients
Phase 4Completed
NCT01438736Merck & Co.Desogestrel 75 micrograms POP

Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?

Start: Sep 201190 patients
Phase 4Unknown
NCT01248351CSL Behringautologous stored platelets

Reversibility of Dual Antiplatelet Therapy by Platelets

Start: Nov 2010Est. completion: Mar 20116 patients
Phase 2Completed
NCT04619108Cellphire TherapeuticsThrombosomes®

Thrombosomes for Expanded Access Use

N/ANo Longer Available
NCT04106895OctapharmaFibryga

Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data

Start: Feb 2019Est. completion: Feb 2020200 patients
N/ACompleted
NCT00448188Heidelberg Pharmacentral venous catheter application

Bleeding Risk in CVCs

Start: Nov 2005Est. completion: Mar 2007200 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space